Cancer Biomarkers Market Size, Trend, and Growth 2023-2028
IMARC Group, a leading market research company, has recently releases report titled “Cancer Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global Cancer Biomarkers market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big Is The Cancer Biomarkers Market?
The global cancer biomarkers market size reached US$ 24.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 12.95% during 2023-2028.
What are Cancer Biomarkers?
Cancer biomarkers refer to biological molecules produced by the cancer or other cells in the body in response to the disease. Peptides, proteins, nucleic acids, enzymes, genes, and specific cells are some of the most commonly used biological molecules. They reveal the presence of cancer in the tissues, blood, or other fluids of the body. Cancer biomarkers are widely used for screening, establishing prognosis, disease diagnosis, monitoring treatment, and detecting the chances of relapse. In addition to this, they also assist healthcare professionals in identifying invasive and non-invasive tumors, tracking the progression of the disease, and recording treatment efficacy. As a result, cancer biomarkers find widespread applications as surrogate endpoints, diagnostics, prognostics, and personalized medicines across the healthcare industry.
Request For A Free Sample Copy Of This Report:https://www.imarcgroup.com/cancer-biomarkers-market/requestsample
What Are The Growth Prospects And Trends In The Cancer Biomarkers Industry?
The escalating incidences of cancer, such as breast, prostate, cervical, lung, and colorectal, and the rising usage of these biological molecules in early detection, managing treatment, and predicting accurate outcomes are primarily driving the cancer biomarkers market. Besides this, the significant shift toward personalized medicine for treating this condition, owing to the lack of standard diagnosis, is further augmenting the market growth. Moreover, continuous technological advancements in genetic biomarker discovery, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), gene expression profiling (microarray), and proteomics, are also catalyzing the global market. Apart from this, the increasing cases of lung cancer, on account of the upsurge in pollution levels, emerging smoking trends, and poor ingestion habits, are acting as significant growth-inducing factors. Additionally, the launch of several policies by the government bodies for enhancing the drug development processes, the growing awareness among healthcare professionals and patients toward the importance of early diagnosis, and the elevating regulatory approvals of novel drugs and diagnostics are expected to bolster the cancer biomarkers market in the coming years.
What Is Included In Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Profiling Technology:
Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics
Breakup by Biomolecule:
Genetic Biomarkers
Protein Biomarkers
Glyco-Biomarkers
Breakup by Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others
Breakup by Application:
Diagnostics
Prognostics
Risk Assessment
Drug Discovery and Development
Others
Breakup by End User:
Hospitals
Academic and Research Institutions
Ambulatory Surgical Centers
Diagnostic Laboratories
Others
Market Breakup by Region:
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
Who Are The Key Players Operating In The Industry?
The report covers the major market players including:
Abbott Laboratories
Agilent Technologies Inc.
Becton Dickinson and Company
bioMérieux SA
Danaher Corporation
Hoffmann-La Roche AG
General Electric Company
Illumina Inc., Qiagen N.V.
Sino Biological Inc.
and Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
Comments
Post a Comment